Albuquerque, NM, March 3, 2026 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces surpassing the 3,000th installation of HALO software worldwide.
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.
Albuquerque, NM, and Hamamatsu City, Japan – 22 May, 2024 – Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the U.S. Food and Drug Administration (FDA) has issued a 510(k) clearance to Indica Labs for HALO AP Dx, an enterprise digital pathology platform.
Albuquerque, NM – 8 May 2024 – Indica Labs, the leading provider of digital pathology solutions, announced today that it received FDA clearance for HALO AP Dx, an enterprise digital pathology platform, for primary diagnosis.
Indica Labs Receives First FDA Clearance for HALO AP Dx Digital Pathology Platform Read More »
